VP at OSO BioPharmaceuticals Elected to DCAT Board of Directors

Albuquerque, NM Nov 1, 2011 – Milton Boyer, vice president of business development at OSO BioPharmaceuticals Manufacturing LLC, has been elected to the board of directors at the Drug, Chemical and Associated Technology Association (DCAT).
Boyer – who is responsible for guiding business strategies and creating new growth opportunities at OsoBio – will serve a three-year term on the board.
Founded in 1891, DCAT is the premier business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical and related industries. More than 300 corporate members belong to DCAT.
“We are delighted to have Mr. Boyer join the organization’s leadership,” said Margaret Timony, executive director. “He brings unique qualifications and experiences to his role that will help shape and support the organization’s programs and projects.”
OsoBio – a contract manufacturing organization specializing in injectable products – manufactures sterile liquid, suspended and lyophilized biologic and pharmaceutical products for the pharmaceutical industry. The company is renowned for its expertise in difficult-to-manufacture, demanding or highly potent products.
After working more than 20 years in fine chemical and pharmaceutical business development, Boyer has developed special expertise in active pharmaceutical ingredients (APIs) and narcotic raw materials. He previously served as director of sales and marketing for Siegfried-USA and Chattem Chemicals Inc.
In addition to his board membership at DCAT, Boyer is a member of the International Society of Pharmaceutical Engineers (ISPE) and the American Association of Pharmaceutical Scientists (AAPS).